ENANTA PHARMACEUTICALS, INC Accrued Royalties, Current
ENANTA PHARMACEUTICALS, INC (ENTA) had Accrued Royalties, Current of $36.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Royalties, Current $36.78M.
- 2026-03-31: Accrued Royalties, Current $31.46M.
- 2025-12-31: Accrued Royalties, Current $31.98M.
- 2025-09-30: Accrued Royalties, Current $30.71M.
| Period end | Accrued Royalties, Current |
|---|---|
| 2026-06-30 | $36.78M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $31.46M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $31.98M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $30.71M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $27.75M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $30.68M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $32.74M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $34.46M 10-K · filed 2025-11-19 |
| 2024-06-30 | $32.30M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $33.67M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $36.51M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $35.08M 10-K · filed 2024-11-27 |
| 2023-06-30 | $36.69M 10-Q · filed 2023-08-08 |
| 2022-09-30 | $0.00 10-K · filed 2023-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |